Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

HMGB1-Mediated Cell Death—A Crucial Element in Post-Hepatectomy Liver Failure
Brunnthaler, Laura, Hammond, Thomas , Probst, Joel, Laferl, Valerie, Resch, Ulrike , Aiad, Monika, Janoschek, Anna Sofie, Gruenberger, Thomas , Hackl, Hubert , Starlinger, Patrick , Assinger, Alice , Hammond, Thomas G , Pereyra, David , Santol, Jonas , Resch, Ulrike , Gruenberger, Thomas , Hackl, Hubert , Starlinger, Patrick , Assinger, Alice , Pereyra, David

International Journal of Molecular Sciences | July 2, 2024 | Volume: 25 | Issue: 13 | Pages: 7150

10.3390/ijms25137150 | PMID 39000266 Get It

Liver resection (LR) is the primary treatment for hepatic tumors, yet posthepatectomy liver failure (PHLF) remains a significant concern. While the precise etiology of PHLF remains elusive, dysregulated inflammatory processes are pivotal. Therefore, we explored the theragnostic potential of extracellular high-mobility-group-box protein 1 (HMGB1), a key damage-associated molecular pattern (DAMP) released by hepatocytes, in liver recovery post LR in patients and animal models. Plasma from 96 LR patients and liver tissues from a subset of 24 LR patients were analyzed for HMGB1 levels, and associations with PHLF and liver injury markers were assessed. In a murine LR model, the HMGB1 inhibitor glycyrrhizin, was administered to assess its impact on liver regeneration. Furthermore, plasma levels of keratin-18 (K18) and cleaved cytokeratin-18 (ccK18) were quantified to assess suitability as predictive biomarkers for PHLF. Patients experiencing PHLF exhibited elevated levels of intrahepatic and circulating HMGB1, correlating with markers of liver injury. In a murine LR model, inhibition of HMGB1 improved liver function, reduced steatosis, enhanced regeneration and decreased hepatic cell death. Elevated levels of hepatic cell death markers K18 and ccK18 were detected in patients with PHLF and correlations with levels of circulating HMGB1 was observed. Our study underscores the therapeutic and predictive potential of HMGB1 in PHLF mitigation. Elevated HMGB1, K18, and ccK18 levels correlate with patient outcomes, highlighting their predictive significance. Targeting HMGB1 enhances liver regeneration in murine LR models, emphasizing its role in potential intervention and prediction strategies for liver surgery.
Spontaneous Coronary Artery Dissection in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of the Literature
Milutinovic, Stefan , Bell, Abraham, Jancic, Predrag , Stanojević, Dragana , Borghol, Abdul Hamid , Mina, Jonathan , Khambati, Ibrahim, Escárcega, Ricardo O. , Bell, Abraham, Chebib, Fouad T. , Wood, Malissa J.

Journal of Personalized Medicine | July 2, 2024 | Volume: 14 | Issue: 7 | Pages: 702

10.3390/jpm14070702 | PMID 39063956 Get It

Spontaneous coronary artery dissection (SCAD) is a spontaneous intimal tear of the coronary artery wall. A factor rarely associated with SCAD is autosomal dominant polycystic kidney disease (ADPKD). Using the PRISMA guidelines, we identified 10 unique cases of SCAD in ADPKD patients reported between 1998 and 2021. Ages ranged from 36 to 59 years, with an average of 44.6 years. The majority of patients were female (80%). Each case was diagnosed with a cardiovascular event: ST-elevation myocardial infarction (STEMI) in 40%, non-ST elevation myocardial infarction (NSTEMI) in 50%, and stable angina in 10%. Conservative management was used in 60% of cases. There is a significant gap in our understanding of the relationship between SCAD and ADPKD. Polycystin complex can lead to structural abnormalities in blood vessels, resulting in vascular leaks and vessel rupture. This suggests that ADPKD patients may have an elevated risk of arteriopathies, including coronary artery dissection.
A Cadaveric Feasibility Study of the Biportal Endoscopic Transfrontal Sinus Approach: A Minimally Invasive Approach to the Anterior Cranial Fossa
Sáez-Alegre, Miguel , Jean, Walter C. , Link, Michael J., Celda, María Peris, Torregrossa, Fábio , Jean, Walter C , Peris Celda, Maria, Pinheiro Neto, Carlos D, Morshed, Ramin A. , Piper, Keaton , Gompel, Jamie J. Van , Pinheiro‐Neto, Carlos

Operative Neurosurgery | July 2, 2024 | Volume: 28 | Issue: 2 | Pages: 175-182

10.1227/ons.0000000000001249 | PMID 38953666 Get It

BACKGROUND AND OBJECTIVES: The trans-sinus transglabellar and bifrontal approaches offer direct access to the anterior cranial fossa. However, these approaches present potential drawbacks. We propose the biportal endoscopic transfrontal sinus (BETS) approach, adapting endoscopic endonasal approach (EEA) techniques for minimally invasive access to the anterior fossa, reducing tissue manipulation, venous sacrifice, and brain retraction. METHODS: Six formalin specimens were used. BETS approach involves 2 incisions over the medial aspect of both eyebrows from the supraorbital notch to the medial end of the eyebrow. A unilateral pedicled pericranial flap is harvested. A craniotomy through the anterior table of the frontal sinus (FS) and a separate craniotomy through the posterior table are performed. Two variants of the approach (preservative vs cranialization) are described for opening and reconstruction of the FS based on the desired pathology to access. Bone flap replacement can be performed with titanium plates and filling of the external table defect with bone cement. RESULTS: Like in EEA, this approach provides access for endoscope and multiple working instruments to be used simultaneously. The approach allows wide access to the anterior cranial fossa, subfrontal, and interhemispheric corridors, all the way up to the suprachiasmatic corridor and through the lamina terminalis to the third ventricle. BETS provides direct access to the anterior fossa, minimizing the level of frontal lobe retraction and providing potentially less tissue disruption and improved cosmesis. Cerebrospinal fluid fistula risk remains one of the major concerns as the narrow corridor limits achieving a watertight closure which can be mitigated with a pedicled flap. Mucocele risk is minimized with full cranialization or reconstruction of the FS. CONCLUSION: The BETS approach is a minimally invasive approach that translates the concepts of EEA to the FS. It allows excellent access to the anterior cranial fossa structures with minimal frontal lobe retraction.
Trigeminal Microvascular Decompression and Meckel's Cave Tumor Resection via Retrosigmoid Approach With Suprameatal Extension: 2-Dimensional Operative Video
Sáez-Alegre, Miguel , Nizzola, Mariagrazia , Driscoll, Colin L. W., Peris‐Celda, Maria , Torregrossa, Fábio , De Bonis, Alessandro, Bonis, Alessandro de, Morshed, Ramin A.

Operative Neurosurgery | July 2, 2024 | Volume: 28 | Issue: 1 | Pages: 135-136

10.1227/ons.0000000000001239 | PMID 38953664 Get It

Hepatitis B Virus Reactivation in Non‐Liver Solid Organ Transplantation: Incidence and Risk Analysis
Chiu, Chia‐Yu , Brumble, Lisa , Vikram, Holenarasipur R. , Watt, Kymberly D. , Beam, Elena , Vikram, Holenarasipur R. , Beam, Elena , Chiu, Chia-Yu

Clinical Transplantation | July 2, 2024 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/ctr.15389 | PMID 38952185 Get It

ABSTRACTIntroductionHepatitis B virus reactivation (HBVr) can occur in solid organ transplant (SOT) recipients with previously inactive hepatitis B virus (HBV) infection. Previous studies have reported that HBVr is generally less than 10% in nonliver SOT recipients with past HBV infection.MethodsWe conducted a retrospective study from January 2018 to August 2023 at Mayo Clinic sites in Arizona, Florida, and Minnesota. We examined the antiviral prophylaxis strategy used and the characteristics of HBVr in hepatitis B core antibody‐positive (HBcAb +) nonliver SOT adult recipients. Past HBV infection was defined as HBcAb + / hepatitis B surface antigen (HBsAg) –. Chronic HBV infection was defined as HBcAb + / HBsAg +.ResultsA total of 180 nonliver SOT recipients were identified during the study period. Indefinite antiviral prophylaxis was utilized in 77 recipients, and none developed HBVr after transplantation. In 103 recipients without antiviral prophylaxis, the incidence of HBVr was 12% (12/97) and 33% (2/6) in those with past HBV infection and chronic HBV infection. The incidence of HBVr in patients with past HBV infection is 16% (8/50), 15% (3/20), and 5% (1/22) in kidney, heart, and lungs, respectively. HBVr was more frequent in those who received alemtuzumab. Among 14 recipients with HBVr, none had HBV‐associated liver failure or death.ConclusionsOur study observed a higher rate of HBVr (12%) in nonliver SOT recipients with past HBV infection compared to the previous studies. Further studies are needed to identify predictors of HBVr in nonliver SOT recipients and optimize antiviral prophylaxis guidance.
Applications of Artificial Intelligence in Medicine: An Expert Panel Discussion
Halamka, John , Kirsh, Susan, Liu, Vincent X. , Simon, Lynn, Halamka, John D , Simon, Lynn T.

The Permanente Journal | July 2, 2024 | Volume: 28 | Issue: 3 | Pages: 3-12

10.7812/tpp/24.068 | PMID 38952203 Get It

Living Donor Decision‐Making and the Complex Interplay of Finances and Other Motivators, Barriers, and Facilitators
Smith, Abigail R. , Mandell, Rebecca , Goodrich, Nathan P. , Helmuth, Margaret , Wiseman, Jonathan B., Fava, Melissa , Ojo, Akinlolu , Merion, Robert M. , Mathur, Amit K. , Mandell, Rebecca J , Helmuth, Margaret E , Fava, Melissa A , Ojo, Akinlolu O , Merion, Robert M , Mathur, Amit , Gifford, Kimberly A.

Clinical Transplantation | July 2, 2024 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/ctr.15377 | PMID 38952192 Get It

ABSTRACTIntroductionThe decision to become a living donor requires consideration of a complex, interactive array of factors that could be targeted for clinical, policy, and educational interventions. Our objective was to assess how financial barriers interact with motivators, other barriers, and facilitators during this process.MethodsData were obtained from a public survey assessing motivators, barriers, and facilitators of living donation. We used multivariable logistic regression and consensus k‐means clustering to assess interactions between financial concerns and other considerations in the decision‐making process.ResultsAmong 1592 respondents, the average age was 43; 74% were female and 14% and 6% identified as Hispanic and Black, respectively. Among employed respondents (72%), 40% indicated that they would not be able to donate without lost wage reimbursement. Stronger agreement with worries about expenses and dependent care challenges was associated with not being able to donate without lost wage reimbursement (OR = 1.2, 95% CI = 1.0–1.3; OR = 1.2, 95% CI = 1.1–1.3, respectively). Four respondent clusters were identified. Cluster 1 had strong motivators and facilitators with minimal barriers. Cluster 2 had barriers related to health concerns, nervousness, and dependent care. Clusters 3 and 4 had financial barriers. Cluster 3 also had anxiety related to surgery and dependent care.ConclusionsFinancial barriers interact primarily with health and dependent care concerns when considering living organ donation. Targeted interventions to reduce financial barriers and improve provider communication regarding donation‐related risks are needed.
STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Chen, Jinghong , Zhu, Lingxuan , Zeng, Dongqiang , Qi, Chang , Tang, Bufu , Shi, Wenjie , Guo, Shipeng, Sun, Xu , Ngo, Trunghieu, Pu, Zhongji , He, Yongbin, Wu, Haiyang , Cheungpasitporn, Wisit, Huang, Haojie , Wang, Shixiang , Cabannes, Loïc, Ren, Gerald Sng Gui , Ali, Stephen R , Cheng, Quan, Miao, Kai , Mou, Weiming , Lin, Anqi , Zeng, Dongqiang, Liu, Zaoqu , Jiang, Aimin , Shi, Wenjie, Kahlert, Ulf D. , Zhou, Jian‐Guo , Lu, Xiaofan , Jia, Baolei , Jeon, Che Ok , Gu, Shuqin , Cheungpasitporn, Wisit , Mao, Weipu , Chen, Xin , Cabannes, Loïc, Whitaker, Iain Stuart , Cheng, Quan, Yuan, Shuofeng , Luo, Peng

iMetaOmics | July 2, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/imo2.7 | PMID 41675544 Get It

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial for ensuring reliable and consistent evaluation of generative AI in healthcare. Our objective is to develop robust, standardized guidelines tailored for evaluating generative AI performance in medical contexts. Through a rigorous literature review utilizing the Web of Sciences, Cochrane Library, PubMed, and Google Scholar, we focused on research testing generative AI capabilities in medicine. Our multidisciplinary team of experts conducted discussion sessions to develop a comprehensive 32‐item checklist. This checklist encompasses critical evaluation aspects of generative AI in medical applications, addressing key dimensions such as question collection, querying methodologies, and assessment techniques. The checklist and its broader assessment framework provide a holistic evaluation of AI systems, delineating a clear pathway from question gathering to result assessment. It guides researchers through potential challenges and pitfalls, enhancing research quality and reporting and aiding the evolution of generative AI in medicine and life sciences. Our framework furnishes a standardized, systematic approach for testing generative AI's applicability in medicine. For a concise checklist, please refer to Table S or visit GenAIMed.org .
A Machine Learning-Based Web Tool for the Severity Prediction of COVID-19
Christodoulou, Avgi, Katsarou, Martha‐Spyridoula , Gavrielatos, Marios , Georgiou, Dimitrios, Tsolakou, Annia , Papasavva, Maria , Economou, Vasiliki, Nanou, Vasiliki, Nikolopoulos, Ioannis , Daganou, Maria , Argyraki, Aikaterini, Stefanidis, Evaggelos, Metaxas, Gerasimos, Panagiotou, Εmmanouil , Michalopoulos, Ioannis , Drakoulis, Nikolaos , Emmanouil, Christina , Georgiou, Dimitrios , Daganou, Maria , Argyraki, Aikaterini , Panagiotou, Emmanouil , Michalopoulos, Ioannis , Drakoulis, Nikolaos , Emmanouil, Christina

BioTech | July 2, 2024 | Volume: 13 | Issue: 3 | Pages: 22

10.3390/biotech13030022 | PMID 39051337 Get It

Predictive tools provide a unique opportunity to explain the observed differences in outcome between patients of the COVID-19 pandemic. The aim of this study was to associate individual demographic and clinical characteristics with disease severity in COVID-19 patients and to highlight the importance of machine learning (ML) in disease prognosis. The study enrolled 344 unvaccinated patients with confirmed SARS-CoV-2 infection. Data collected by integrating questionnaires and medical records were imported into various classification machine learning algorithms, and the algorithm and the hyperparameters with the greatest predictive ability were selected for use in a disease outcome prediction web tool. Of 111 independent features, age, sex, hypertension, obesity, and cancer comorbidity were found to be associated with severe COVID-19. Our prognostic tool can contribute to a successful therapeutic approach via personalized treatment. Although at the present time vaccination is not considered mandatory, this algorithm could encourage vulnerable groups to be vaccinated.
Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event (AE)-based analysis.
Munir, Tahla, Mohseninejad, Leyla, Srivastava, Tushar , Gupta, Anurag , Gautam, Raju, Challagulla, Swetha, Mei, Xue , Yang, Keri, Williams, Rhys , Wang, Yucai , Xue, Mei, Williams, Rhys , Lévy, Vincent , Zhou, Shouhao

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e19049-e19049

10.1200/jco.2024.42.16_suppl.e19049 Get It

e19049 Background: Acala and zanu are 2nd generation Bruton tyrosine kinase inhibitors (BTKis) that have demonstrated improved safety profiles vs 1st generation BTKi ibrutinib in clinical trials. While head-to-head comparison of zanu vs acala is lacking, a recent meta-analysis of clinical trials provided a comprehensive, indirect comparison of the AE profiles in B-cell malignancies (Hwang, Hemasphere. 2023;7(S3):1134). This study aims to evaluate costs and impacts on quality of life (QoL) for zanu vs acala using their AE profiles. Methods: A health economic model was developed to determine cost and QoL associated with AE management for zanu and acala. The incidence rates ( IRs) of all grade and grade ≥3 AEs of interest (n=21, including bleeding events, hypertension, atrial fibrillation, cytopenias, infections, headache, arthralgia, diarrhea) were taken from the meta-analysis. Additional model inputs, such as disutility, average duration of AE, and unit cost of each AE were sourced from published literature and publicly available cost databases in consultation with clinical experts. The model was developed from the US perspective, considering Medicare costs, inflated to 2023 USD. Model outcomes were AE management cost (= IR * unit cost) and quality-adjusted life years (QALYs) lost due to AE (= IR * Disutility * Duration/365.25). Results: In the base-case scenario (considering all AEs), treating a hypothetical cohort of 1000 patients (pts) with zanu instead of acala yielded cost savings of $124K and 3.7 QALY gains (i.e., 3.7 years extra in full health). Subgroup analysis for severe (grade ≥3) and non-severe AEs (grade 1-2) demonstrated similar trends. A sensitivity analysis limited to AEs significantly different between zanu and acala (n=13) yielded consistent results. Additionally, a probabilistic sensitivity analysis, conducted with 1000 iterations to account for uncertainty in model parameters, confirmed robustness of the model, indicating stable conclusions across a wide range of parameter uncertainties. Conclusions: This analysis suggested that zanu is cost-saving and associated with added health benefits compared to acala in terms of AE management in pts with B-cell malignancies. Should these results derived from meta-analysis of clinical trial data be applicable to real-world pt populations across different indications, the potential cost savings could be considerable. These results could be further improved if the differences in efficacy of zanu vs acala are also incorporated. [Table: see text]